Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00472836 · ClinicalTrials.gov registry record · Phase 1
Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00472836 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 17 participants.
The verdict
NCT00472836, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
CP-945,598 is eliminated following extensive metabolism. For some drugs, decreased renal (kidney) function can affect their elimination from the body via metabolism. This study will therefore compare the pharmacokinetics (time course of drug concentrations in the body), safety and tolerability of CP-945,598 in patients with severe renal impairment and healthy control subjects.
Interventions
- DRUG CP-945,598
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00472836
The ClinicalTrials.gov registry entry for NCT00472836 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-945,598 is the first listed.
NCT00472836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00472836 about?
NCT00472836 is a clinical study titled "Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug". CP-945,598 is eliminated following extensive metabolism. For some drugs, decreased renal (kidney) function can affect their elimination from the body via metabolism. This study will therefore compare the pharmacokinetics (time course of drug concentrations in the body), safety and tolerability of CP...
What is the current status of trial NCT00472836?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2007-06. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00472836?
The interventions under investigation include: CP-945,598 (DRUG).
Who is sponsoring clinical trial NCT00472836?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.